Hilton Head Capital Partners’s Novavax NVAX Stock Holding History

Hilton Head Capital Partners’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.83K	Hold	300	–	–	﹤0.01%	737
2026 Q1	$2.44K	Hold	300	–	–	﹤0.01%	778
2025 Q4	$2.02K	Buy	+300	New	+$2.26K	﹤0.01%	753

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Hilton Head Capital Partners's NVAX Position: Q2 2026 in Review

Hilton Head Capital Partners held its Novavax (NVAX) position steady in Q2 2026 at 300 shares worth $2.83K. The position accounts for ﹤0.01% of the portfolio, ranked #737.

Hilton Head Capital Partners first reported a position in NVAX in Q4 2025 and has held it in 3 quarters since. 265 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

Hilton Head Capital Partners held 300 shares of Novavax worth $2.83K as of Q2 2026.
Hilton Head Capital Partners left its Novavax share count unchanged in Q2 2026.
Novavax made up ﹤0.01% of Hilton Head Capital Partners's portfolio in Q2 2026, its #737 holding.
Hilton Head Capital Partners first reported a position in Novavax in Q4 2025 and has held it in 3 quarters since.
265 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Hilton Head Capital Partners's 13F filing for Q2 2026, filed 27 Jul 2026.